MEDICARE UTILIZATION · PART B · 2024
No data available for this provider in 2024.
PRESCRIBING · PART D · 2024
Total Rx claims
3,163
Beneficiaries
—
Total drug cost
$4.3M
Distinct drugs
68
Brand share
53.0%
Top prescribed drugs
Dolutegravir Sodium/Lamivudine323 claims
Rosuvastatin Calcium255 claims
Bictegrav/Emtricit/Tenofov Ala224 claims
Dolutegravir Sodium151 claims
Emtricitabine/Tenofov Alafenam129 claims
QUALITY · MIPS · 2024
Final MIPS score
82.5
Quality
64.8
Cost
79.2
Improvement activities
40.0
Promoting interop.
0.0
Payment adjustment
0.32%
Group
CROSS-REFERENCE